...
首页> 外文期刊>Clinical Laboratory Science: Journal of the American Society for Medical Technology >A guide for diagnosis of patients with arterial and venous thrombosis.
【24h】

A guide for diagnosis of patients with arterial and venous thrombosis.

机译:动脉和静脉血栓形成患者的诊断指南。

获取原文
获取原文并翻译 | 示例

摘要

Inasmuch as coagulation laboratories are involved in providing a diagnosis for underlying causes of venous and arterial thrombosis, we present a comprehensive review of the biological properties and functions of the components of the hemostatic system as they relate to the diagnosis of arterial and venous thrombosis. Moreover, as coagulation laboratories are necessary to evaluate the success of initial treatment modalities and to provide guidance for supplemental therapeutic intervention, we include information on antiplatelet and antithrombotic therapy. Included in clinical coagulation testing are assays that evaluate the potential of blood to form clots and tests for platelet numbers and platelet functions. Clot-based assays directly detect the biological activity of procoagulant factors and fibrinogen; chromogenic substrate assays evaluate proteolytic activities of clotting as well as fibrinolysis enzymes; and specific antibodies measure the concentrations of coagulation and fibrinolysis enzymes in plasma. Genetic testing is rapidly becoming incorporated into the clinical routine. The prothrombin time (PT), activated partial prothrombin time (APTT), and thrombin time (TT) are screening assays that measure the clotting times of recalcified whole blood or platelet-poor plasma. In addition to their function as screening assays, PT, APTT, and TT are the backbone of all the specialized clot-based assays for factor activities and for the indirect measurement of inhibitory antithrombin and protein C activities. Molecular markers related to hemostasis and fibrinolysis consist of proteins or peptides that indicate an ongoing physiological or abnormal process related to clot formation, thrombosis, vascular damage, or drug effect. Molecular markers are currently identified by means of specific antibodies prepared against them. The list of hemostatic molecular markers is rapidly growing. Most of the assays developed for molecular marker measurement, with the notable exception of the d-dimer assay, are typically used in clinical research.
机译:由于凝血实验室参与了对静脉和动脉血栓形成的根本原因的诊断,因此,我们对止血系统各组成部分的生物学特性和功能进行了全面的综述,因为它们与动脉和静脉血栓形成的诊断有关。此外,由于凝血实验室对于评估初始治疗方式的成功性并为补充治疗干预提供指导是必要的,因此我们提供了有关抗血小板和抗血栓治疗的信息。临床凝血测试中包括评估血液形成血块的潜力的测定法,并测试血小板数量和血小板功能。基于凝块的分析直接检测促凝血因子和纤维蛋白原的生物学活性;生色底物测定法可评估凝血蛋白水解酶以及纤溶酶的活性;特异性抗体可测量血浆中凝血酶和纤溶酶的浓度。基因检测正迅速纳入临床程序。凝血酶原时间(PT),活化部分凝血酶原时间(APTT)和凝血酶时间(TT)是筛选测定,可测量重新钙化的全血或贫血小板血浆的凝血时间。 PT,APTT和TT除了具有筛选检测功能外,它还是所有基于凝块的专门检测方法的基础,可用于因子活性以及间接测量抑制性抗凝血酶和C蛋白活性。与止血和纤维蛋白溶解有关的分子标记物由蛋白质或肽组成,这些蛋白质或肽表明与血块形成,血栓形成,血管损伤或药物作用有关的正在进行的生理过程或异常过程。目前,通过针对它们制备的特异性抗体来鉴定分子标记。止血分子标志物的清单正在迅速增长。除d-二聚体测定法外,大多数为分子标记物测量而开发的测定法通常用于临床研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号